ProPhase Labs, Inc. (PRPH)
PRPH Stock Price Chart
Explore ProPhase Labs, Inc. interactive price chart. Choose custom timeframes to analyze PRPH price movements and trends.
PRPH Company Profile
Discover essential business fundamentals and corporate details for ProPhase Labs, Inc. (PRPH) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
4 Apr 1994
Employees
96.00
Website
https://www.prophaselabs.comCEO
Ted William Karkus
Description
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
PRPH Financial Timeline
Browse a chronological timeline of ProPhase Labs, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 18 May 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.11.
Earnings released on 13 Aug 2025
EPS came in at -$0.11 surpassing the estimated -$0.15 by +26.67%, while revenue for the quarter reached $1.25M , missing expectations by -78.08%.
Earnings released on 20 May 2025
EPS came in at -$0.12 surpassing the estimated -$0.18 by +33.33%, while revenue for the quarter reached $1.43M , missing expectations by -59.69%.
Earnings released on 31 Mar 2025
EPS came in at -$0.51 falling short of the estimated -$0.24 by -112.50%, while revenue for the quarter reached -$2.48M , missing expectations by -201.39%.
Earnings released on 13 Nov 2024
EPS came in at -$0.35 falling short of the estimated -$0.31 by -12.90%, while revenue for the quarter reached $3.15M , missing expectations by -46.50%.
Earnings released on 14 Aug 2024
EPS came in at -$0.33 falling short of the estimated -$0.08 by -312.50%, while revenue for the quarter reached $2.47M , missing expectations by -77.85%.
Earnings released on 9 May 2024
EPS came in at -$0.07 surpassing the estimated -$0.28 by +75.00%, while revenue for the quarter reached $3.63M , missing expectations by -9.15%.
Earnings released on 28 Mar 2024
EPS came in at -$0.51 falling short of the estimated -$0.26 by -96.15%, while revenue for the quarter reached $3.50M , missing expectations by -67.27%.
Earnings released on 9 Nov 2023
EPS came in at -$0.30 falling short of the estimated -$0.20 by -50.00%, while revenue for the quarter reached $8.37M , missing expectations by -21.75%.
Earnings released on 10 Aug 2023
EPS came in at -$0.20 falling short of the estimated -$0.14 by -42.86%, while revenue for the quarter reached $13.22M , missing expectations by -6.53%.
Earnings released on 11 May 2023
EPS came in at $0.03 surpassing the estimated -$0.09 by +133.33%, while revenue for the quarter reached $19.30M , beating expectations by +18.42%.
Earnings released on 28 Mar 2023
EPS came in at -$0.08 falling short of the estimated -$0.01 by -580.27%, while revenue for the quarter reached $21.82M , beating expectations by +6.40%.
Earnings released on 10 Nov 2022
EPS came in at $0.06 falling short of the estimated $0.19 by -68.42%, while revenue for the quarter reached $24.20M , beating expectations by +17.99%.
Earnings released on 11 Aug 2022
EPS came in at $0.40 surpassing the estimated $0.18 by +122.22%, while revenue for the quarter reached $29.09M , beating expectations by +45.37%.
Earnings released on 13 May 2022
EPS came in at $0.68 surpassing the estimated $0.39 by +74.36%, while revenue for the quarter reached $47.53M , beating expectations by +95.52%.
Dividend declared on 13 May 2022
A dividend of $0.30 per share was announced, adjusted to $0.30. The dividend was paid on 3 Jun 2022.
Earnings released on 30 Mar 2022
EPS came in at $0.44 surpassing the estimated $0.36 by +22.22%, while revenue for the quarter reached $45.16M , beating expectations by +57.83%.
Dividend declared on 16 Feb 2022
A dividend of $0.30 per share was announced, adjusted to $0.30. The dividend was paid on 10 Mar 2022.
Earnings released on 12 Nov 2021
EPS came in at -$0.26 falling short of the estimated $0.07 by -471.43%, while revenue for the quarter reached $9.47M , beating expectations by +4.32%.
Earnings released on 13 Aug 2021
EPS came in at -$0.09 falling short of the estimated $0.19 by -147.37%, while revenue for the quarter reached $9.14M , meeting expectations.
Earnings released on 13 May 2021
EPS came in at $0.23 falling short of the estimated $0.35 by -34.29%, while revenue for the quarter reached $15.27M , beating expectations by +40.00%.
Dividend declared on 13 May 2021
A dividend of $0.30 per share was announced, adjusted to $0.30. The dividend was paid on 3 Jun 2021.
Earnings released on 31 Mar 2021
EPS came in at -$0.23 falling short of the estimated -$0.02 by -1.05K%, while revenue for the quarter reached $5.16M .
Earnings released on 16 Nov 2020
EPS came in at -$0.05 , while revenue for the quarter reached $3.84M .
PRPH Stock Performance
Access detailed PRPH performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.